Novel missense mutation in the coagulation factor IX catalytic domain associated with severe haemophilia B -: Factor IXDelhi

被引:2
|
作者
Mahajan, A
Sharma, A
Chavali, S
Kabra, M
Chowdhury, MR
Srinivasan, N
Bharadwaj, D
机构
[1] Inst Genom & Integrat Biol, Funct Genom Unit, Delhi 110007, India
[2] All India Inst Med Sci, Dept Pediat, Genet Unit, New Delhi, India
[3] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India
关键词
factor IXa; catalytic domain; blood coagulation; homology modelling;
D O I
10.1111/j.1365-2516.2004.00948.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor IX is a vitamin K-dependent serine protease, which exists as a zymogen in the blood. On activation to factor IXa, by factor XIa or tissue factor-factor VIIa complex, it forms tenase complex with factor VIIIa, in the presence of Ca2+. This tenase complex enzymatically converts factor X to factor Xa, thereby bringing about the coagulation cascade. Mutations in factor IX gene have been shown to cause haemophilia B, which is inherited as an X-linked recessive disorder. Herein we report a novel missense mutation at the nucleotide position 30829-T > A in the exon 8 of factor IX gene. This transversion leads to the substitution of histidine 236 to glutamine. This resulting abnormal protein has been named factor IXDelhi. Molecular modelling was performed to predict the molecular pathology of this mutation. We predict that this change in the catalytic domain may affect the surface loop that accommodates Ca2+, thereby leading to severe bleeding disorder.
引用
收藏
页码:550 / 552
页数:3
相关论文
共 50 条
  • [41] A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism
    Yaish, H.
    Rodgers, G. M.
    HAEMOPHILIA, 2008, 14 (03) : 607 - 609
  • [42] MUTATION DETECTION IN PROMOTER REGION OF COAGULATION FACTOR IX IN HEMOPHILIA B PATIENTS IN IRAN
    Farsani, M. Allahbakhshian
    Rastegar, G.
    Kazemi, A.
    Ala, F.
    Mohammadi, M.
    Ravanbood, S.
    Allahbakhshian, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 553 - 553
  • [43] Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B
    Barnbrock, A.
    Heller, C.
    Koenigs, C.
    Budde, U.
    Schwabe, D.
    HAEMOPHILIA, 2016, 22 (05) : E437 - E439
  • [44] Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China
    Dou, Xueqing
    Zhang, Wenhui
    Poon, Man-Chiu
    Zhang, Xinsheng
    Wu, Runhui
    Feng, Xiaoqin
    Yang, Linhua
    Cheng, Peng
    Chen, Shu
    Wang, Ying
    Zhou, Hu
    Huang, Meijuan
    Song, Yanping
    Jin, Chenghao
    Zhang, Donglei
    Chen, Lingling
    Liu, Wei
    Zhang, Lei
    Xue, Feng
    Yang, Renchi
    HAEMOPHILIA, 2023, 29 (01) : 123 - 134
  • [45] Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B
    Walker, J. A.
    Dixon, N.
    Gururangan, S.
    Thornburg, C.
    HAEMOPHILIA, 2008, 14 (02) : 387 - 389
  • [46] Treatment of intracranial and extracranial haemorrhages in a neonate with severe haemophilia B with recombinant factor IX infusion
    Guilcher, GMT
    Scully, MF
    Harvey, M
    Hand, JP
    HAEMOPHILIA, 2005, 11 (04) : 411 - 414
  • [47] Severe factor VII deficiency caused by a novel mutation His348 to Gln in the catalytic domain
    Katsumi, A
    Matsushita, T
    Yamazaki, T
    Sugiura, I
    Kojima, T
    Saito, H
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 239 - 243
  • [48] Genetic analysis of the coagulation factor VIII and IX genes in Hungarian families with haemophilia
    Bors, A.
    Andrikovics, H.
    Szilvasi, A.
    Illes, Zs.
    Marosi, A.
    Nemes, L.
    Tordai, A.
    BLOOD REVIEWS, 2007, 21 : S70 - S70
  • [49] Consequences of factor IX mutations in 26 families with haemophilia B
    Weinmann, AF
    Murphy, MEP
    Thompson, AR
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (01) : 58 - 61
  • [50] An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B
    Lissitchkov, T.
    Matysiak, M.
    Zawilska, K.
    Gercheva, L.
    Antonov, A.
    Montanes, M.
    Paez, A.
    HAEMOPHILIA, 2010, 16 (02) : 240 - 246